title: Inhibition of canine exocrine pancreatic secretion by peptide YY is mediated by PYY-preferring Y2 receptors.
abstract: It is still unclear, which receptor subtype, Y1 and/or Y2, mediates the inhibitory action of PYY on exocrine pancreatic secretion. The present study was undertaken to characterize functionally the Y receptor subtype that mediates the inhibition of exocrine pancreatic secretion by peptide YY (PYY). In eight conscious dogs with chronic gastric and pancreatic fistulas, we compared the action of intravenous infusion of 200 and 400 pmol/kg/h of the Y receptor agonists PYY 1-36, PYY 3-36, PYY 13-36, Pro34PYY 1-36, and NPY 1-36 on the pancreatic secretory response to secretin (20.5 pmol/kg/h) and cerulein (29.6 pmol/kg/h). PYY 13-36, Pro34PYY 1-36, and NPY 1-36 were also studied by giving a fivefold dose (1,000 and 2,000 pmol/kg/h). PYY 1-36 and the Y2 receptor agonist PYY 3-36 significantly inhibited pancreatic secretory responses to secretin and cerulein, whereas inhibition by NPY 1-36 and the Y2 receptor agonist PYY 13-36 was attainable only at doses of 1,000 and 2,000 pmol/kg/h. The Y1 receptor agonist Pro34PYY 1-36 was without effect on pancreatic secretion. We conclude that in dogs the inhibition of exocrine pancreatic secretion by PYY is mediated via Y2 receptors of a PYY-preferring subtype.
authors.affiliation: Department of Medicine IV (Gastroenterology), University Hospital of Heidelberg at Mannheim, Theodor Kutzer Ufer, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Teyssen
authors.forename: D
authors.initials: D
authors.lastname: Grandt
authors.forename: E
authors.initials: E
authors.lastname: Niebergall-Roth
authors.forename: M
authors.initials: M
authors.lastname: Schimiczek
authors.forename: H
authors.initials: H
authors.lastname: Goebell
authors.forename: V E
authors.initials: VE
authors.lastname: Eysselein
authors.forename: J R
authors.initials: JR
authors.lastname: Reeve
authors.forename: M V
authors.initials: MV
authors.lastname: Singer
mesh_terms: D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D002108:Ceruletide / Q000494:pharmacology; D004285:Dogs; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D009478:Neuropeptide Y / Q000097:blood / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology; D019894:Peptide YY; D010455:Peptides / Q000097:blood / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000187:drug effects* / Q000502:physiology*; D012633:Secretin / Q000494:pharmacology
chemical_list: D001639:Bicarbonates; D009478:Neuropeptide Y; D010446:Peptide Fragments; D010455:Peptides; D011506:Proteins; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor; D019894:Peptide YY; D012633:Secretin; D002108:Ceruletide